Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tidal Therapeutics

Novartis building

FDA deems Novartis lung cancer drug a “breakthrough therapy”

LDK378 will have accelerated passage through development

- PMLiVE

Bayer fails to overturn Nexavar compulsory licence in India

Natco Pharma allowed to sell cut-price version of cancer drug

- PMLiVE

Roche gains EU approval for Perjeta in breast cancer

Available in combination with Herceptin and docetaxel chemotherapy

- PMLiVE

Novo’s Lantus rival Tresiba hits European markets

Company says its insulin degludec is a more flexible alternative to Sanofi's product

- PMLiVE

Sanofi gets EMA backing for multi-disease vaccine in children

Hexyon-Hexacima 6-in-1 paediatric vaccine recommended for approval in Europe

Roche - Basel

Roche’s Herceptin follow-up cleared in US

FDA approval for Kadcyla (formerly T-DM1) in breast cancer

- PMLiVE

Late-stage failure for Merck’s cilengitide in brain cancer

Integrin inhibitor unable to improve overall survival in phase III trials

Sanofi reception

FDA to review Sanofi’s lixisenatide for diabetes

Follows drug's European approval under brand name Lyxumia earlier this month

- PMLiVE

Genzyme on track for eliglustat filing in 2013

Says oral Gaucher disease drug as effective as its injectable Cerezyme

- PMLiVE

FDA fast-tracks Bayer’s prostate cancer radiotherapy

Priority review for radium-223 dichloride, formerly called Alpharadin

e-Therapeutics raises £40m to support oncology pipeline

Will fund development of ETS2101 for brain cancer and other potential indications

Just Health PR wins Caris Life Sciences brief

Bioscience company to launches its tumour profiling technology in Europe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links